PubMed Health⌕ Search

Biomedical subjects

Timothy Schofield

Publications and source records attributed to Timothy Schofield.

2 recordsLinked to original sources

Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).

A sensitive and reproducible method to determine the in vitro infectious potency of a pentavalent reassortant rotavirus vaccine (RotaTeq) has been developed as an alternative to classical potency assays. Potency was determined based on cell-based viral replication followed by quantitative reverse-transcription polymerase chain reaction (RT-QPCR) analysis. In the assay, confluent Vero cell monolayers in 96-well plates were inoculated with serial dilutions of test samples, a pentavalent reassortant rotavirus reference standard and assay controls, followed by incubation for 24h. The cells were lysed with a Triton X-100 solution and the lysates assayed by RT-QPCR to quantitate viral nucleic acid produced during replication. The RT-QPCR utilizes primer/probe sets specific to each virus reassortant and the potencies of each sample were determined relative to the reference standard. This assay, hereafter referred to as the Multivalent QPCR-Based Potency Assay (M-QPA), permits the specific quantitation of each individual reassortant virus in the presence of the other four reassortant viruses. In addition, the assay was demonstrated to be concordant with a traditional method (plaque assay) for the quantitation of infectious virus particles. It is anticipated that assays of this type will become a valuable tool in the assignment of potency values and in the monitoring of stability of live virus vaccines.

Animals↗

Pharmaceutical stability testing conference.

The Pharmaceutical Stability Testing conference organised by SMi was held on the 8th and 9th of September 2003 in London. The focus of the conference was on stability testing issues related to both compound drugs and biopharmaceuticals and the impact of stability testing on product development and commercialisation. The conference brought two days of presentations given by formulation, process, analytical, quality and regulatory professionals from both the European and US pharmaceutical industries. The presentations discussed various issues related to pharmaceutical stability testing in early stage preclinical development, during clinical studies and in late stage development for regulatory filing. The discussions covered biologicals and small molecules, drug substance and drug product, with supporting case studies.

Drug Approval↗